EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
Recent Searches
EY R&D Workbench for Pharma
The EY R&D Workbench for Pharma is a unique tech solution for effective project planning management, workflow and issue and query tracking in the R&D environment. It leads to improved market speed and increased transparency and accountability throughout various organizations involved in formulation (across multiple dosage forms), API and biosimilar.
What EY can do for you
In the pharma sector, R&D processes are often siloed, leading to suboptimal outcomes. Roles and responsibilities are not clearly defined, leading to slow down in the growth of organization. EY R&D Workbench provides a holistic solution to transform the R&D ecosystem by providing opportunities like:
EY R&D Workbench has successfully resolved critical issues of the pharma sector, leading to efficient processes and tangible impact.
EY R&D Workbench is a one-stop cross-departmental collaborative platform to monitor and keep pace with the dynamically transforming R&D environment with enhanced transparency and accountability throughout the organization.
Key features:
- Project management module
- New product development module
- New product launch module
- Clinical workbench module
- Regulatory workbench module
- Functional capabilities
- User and leadership dashboards
- Digitize portfolio management by integrating IMS data and other databases
- Manage portfolios via customizable method upload, validation flow, molecule-level backend, dynamic exclusion based on market analysis, and representative display with confirmation/ versioning
- Include product selection, technical evaluation, complexity assessment, commercial evaluation, and PIF as part of portfolio evaluation and product selection modules
- Implement predictive risk assessment
- Track R&D with project management, automated processes, predefined SLAs, and issue tracking
- Digitize workflows, integrate with tools like SAP, LIMS, ELN
- Use customized templates for various dosage forms and markets
- Manage launch activities with project management, online team selection, task allocation, SLAs, and stage gate approvals
- Digitize workflows, maintain audit trails, integrate with ERP tools
- Utilize customizable activity templates tailored for markets and launches
- Monitor clinical activities across teams, sites, countries, and clients
- Utilize established workflows, stages, milestones, SLAs, and ownership for each clinical phase and dosage type.
- Track dossier submission, deficiency management, and post-approval activities
- Define workflows, stages, milestones, SLAs, and ownership for each market/ vertical/ type of dosage
- Integrate with quality management and document management systems
- Portfolio and Project management functionality
- Collaboration with workflows
- Basic project management functionality
- Re-baselining with version history and change management
- Issue tracking
- Timesheet module for effective utilization
- Admin modules and user management
- Digitized and automated notifications and escalations
- Budget allocation and monitoring
- Document upload
- Tailored reports and dashboards with features like search queries, analytics overviews, and budgeting.
- Detailed workflows for administrative tasks like SLA changes and approvals.
- Role-specific dashboards providing actionable updates and status visibility for ongoing and upcoming tasks.
Why EY
R&D has been a key focus area for most Indian pharma companies. Though India is a leader in terms of ANDA approvals globally, there is a significant scope for improving the same to achieve faster launches. We have been working with leading pharma companies to transform their R&D organizations. As a part of the transformation program, we have delivered a reduction in end-to-end timelines (Initiation to Launch) of ~15 to 20%, improving FTR (First Time Right) to >85% across R&D processes. We look at R&D from an enterprise-wide perspective, including critical elements of people, process, and technology.
The typical transformation journey kicks off by re-designing the organization structure to support the agreed to-be processes. Once the same is implemented, the processes are enabled with an EY proprietary tool called “R&D Workbench for Pharma.” It is a unique solution, led by experienced professionals with strong global experience of working in R&D technology enablement programs and change management. EY has empowered organizations with several such fit-for-purpose tech platforms and tools, boosting their end-to-end process capabilities.
Our latest thinking
India’s MedTech transformation: paving the path to global leadership
India's MedTech industry is undergoing a revolution. Explore the latest trends, government support, and the potential for global dominance. Learn more.
Confronting India’s cancer crisis: The urgent need for affordable care
India battles rising cancer rates. Learn about challenges, prevention, early detection, and affordable treatment options. Know more.
Transforming healthcare in India with Generative AI
Leverage GenAI in Indian healthcare: a collaborative strategy for high-quality, accessible care, balancing potential with mindful tech integration. Learn more.
Explore our case studies
How a manufacturer eliminates cost and value leakages with AI-ML
Discover how EY AI-enabled tool helps a roofing solutions manufacturer improve production efficiency while maintaining quality standards. Learn more about AI in manufacturing use case.
How a young cement company grew 2.5x with organizational and functional transformation
Learn how EY helped a young cement manufacturer grew production capacity by 2.5x facilitated by data-driven transformation.
How a state government transformed into an ecotourism haven
Discover how EY helped a state government accelerate its economy and create new sources of employment through ecotourism. Learn more about sustainable tourism.
Our team
Direct to your inbox
Stay up to date with our Editor's picks newsletter.